|
Ä¿¸®¾îHR |
Ä¿¸®¾îHR] Healthy Supplementary RA
¼¿ï °³²±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
4³â¡è |
ä¿ë½Ã |
03.26 |
|
|
¹ÙÀÌ¿ÀÀÌÁî |
¹ÙÀÌ¿ÀÀÌÁî Á¦¾à/¹ÙÀÌ¿À ±âȹÆÀ¿ø ¸ðÁý
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
4³â¡è |
ä¿ë½Ã |
05.10 |
|
|
(ÁÖ)Ƽ¿¤½Ã½ºÅÛ |
Ç°Áú°æ¿µºÎ¹® °æ·ÂÀÚ
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
4³â¡è |
ä¿ë½Ã |
10.28 |
|
|
(ÁÖ)Á¨Å¥¸¯½º |
Ç°Áúº¸Áõ(QA)´ã´çÀÚ ¿ì¼öÀÎÀç ¸ðÁý
¼¿ï ±¸·Î±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
4³â¡è |
ä¿ë½Ã |
03.08 |
|
|
ÆÄ·º¼¿ ÄÚ¸®¾Æ |
ÆÄ·º¼¿ ÄÚ¸®¾Æ - Clinical Lead
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
09.13 |
|
|
ÁÖ½Äȸ»ç ¿À»óÇコÄɾî |
QA ºÐ¾ß °æ·ÂÁ÷ ä¿ë
°æ±â ¾È¾ç½Ã µ¿¾È±¸ | ´ëÇÐ(4³â) ÀçÇÐ |
ÀÓ»ó BD/RA/QA |
4³â¡è |
ä¿ë½Ã |
09.13 |
|
|
¾ÈÆ®·ÎÁ¨ |
ÀÓ»óÆÀ ä¿ë°ø°í
¼¿ï °¼±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
04.26 |
|
|
Á¸½¼¾ØµåÁ¸½¼¸ÞµðÄ® |
Á¸½¼¾ØµåÁ¸½¼¸ÞµðÄ® HEMA Manager (Health Economic Market
¼¿ï ¿ë»ê±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
»ç¹«/Ãѹ«/¹ý¹«/ƯÇã |
4³â¡è |
ä¿ë½Ã |
04.17 |
|
|
Pharmax Ogilvy Healthworld |
Market Research Unit head (Â÷ºÎÀå±Þ)
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿¬±¸/¿¬±¸±âȹ |
4³â¡è |
ä¿ë½Ã |
02.21 |
|
|
(ÁÖ)´ºÆ®¸®¹ÙÀÌ¿ÀÅØ |
´ºÆ®¸®¹ÙÀÌ¿ÀÅØ °æ¿µ±âȹ °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°æ¿µ/Àü·«±âȹ/ÄÁ¼³Æà |
4³â¡è |
ä¿ë½Ã |
01.17 |
|
|
Ä¿¸®¾îHR |
°æ±â ÀüÁö¿ª | ´ëÇÐ(2~3³â) ÀçÇÐ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
4³â¡è |
ä¿ë½Ã |
01.23 |
|
|
Ä¿¸®¾îHR |
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
¿µ¾÷°ü¸®/¿µ¾÷Áö¿ø |
4³â¡è |
ä¿ë½Ã |
12.29 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] ÀÓ»ó Project Manager ä¿ë
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
4³â¡è |
ä¿ë½Ã |
07.07 |
|
|
(ÁÖ) »ç³ëÇÇ-¾Æº¥Æ¼½ºÄÚ¸®¾Æ |
[Sanofi/»ç³ëÇÇ] RA Specialist
¼¿ï ¼Ãʱ¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
3³â¡è |
ä¿ë½Ã |
01.02 |
|
|
(ÁÖ)¼¸°¹ÙÀÌ¿À»çÀ̾𽺠|
Research Flow Cytometry ¸¶ÄÉÆà ´ã´çÀÚ
°æ±â ¼º³²½Ã ºÐ´ç±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
10.18 |
|